Dry Eye Disease Clinical Landscape Report 2026: Trials, Readouts and White Space

Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.

Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.

Executive view

Dry Eye Disease remains an active clinical development field. The strongest programs are pairing biologically differentiated interventions with patient-centered outcomes, less burdensome delivery and longer evidence windows. The PatSnap evidence set used here contains 916 matched trial records and 444 indexed result records before the decision-focused sample below was selected.

How PatSnap MCP built this report

The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.

Trial landscape table

The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.

What indexed results say

• A Phase 4, Multicenter, Open-Label Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/ Keratometry and Postoperative Refractive Accuracy (Phase 4): the indexed record reports -; Mean Difference Between Absolute Deviations From Predicted Refractive Error in the Study Eye.(Mean) = -0.027 Diopters (Standard Deviation, 0.167); -.
• Randomized Multicenter Double-Masked Placebo-Controlled Parallel Phase I/II Study to Determine the Safety and Exploratory Efficacy of Topical Fibrinogen Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs Host Disease (Phase 1/2): the indexed record reports Number of Participants With Ocular Treatment-related Adverse Events as Assessed by CTCAE v4.0 = 1 Participants; Number of Participants With Ocular Treatment-related Adverse Events as Assessed by CTCAE v4.0 = 1 Participants; -.
• ANIFROLUMAB TREATMENT IN PATIENTS WITH SJÖGREN’S DISEASE: EFFICACY AND SAFETY ASSESSMENT IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE IIA PROOF-OF-MECHANISM TRIAL (ANISE-II) (Phase 2): the indexed record reports CRESS response(12-week) = 10.0 %; CRESS response(12-week) = 65.0 %.

Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.

Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.

Asset and sponsor context

PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including The selected trials include interventions that are not yet normalized to an asset record. Company & Deal Intelligence records identify sponsor context for Wenzhou Medical University’s affiliate Eye hospital Zhejiang, Anhui USTC EGI Biotechnology Co., Ltd., The First Affiliated Hospital of Xiamen University. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.

Where the white space is

1. Endpoints that capture daily function and treatment burden alongside biological change.
2. Long-duration comparisons against current procedural or pharmacologic standards.
3. Evidence across diverse ages, disease stages and reproductive contexts.
4. Delivery approaches that improve persistence without sacrificing safety.

Strategic implications

For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.

What to monitor next

Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.

Bottom line

Dry Eye Disease has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.